Pharmacokinetic interactions of dasatinib and docetaxel

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages

  Levêque, Dominique ^a  

^a Pharmacologie Clinique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DASATINIB; DOCETAXEL; IMATINIB;

ADVANCED CANCER; DRUG ACTIVITY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; HUMAN; KINETICS; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84892959866     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70004-X     Document Type: Letter

References (5)

1. Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 2013, 14:1307-1316.
2. Baker SD, Sparreboom A, Verweij J Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006, 45:235-252.
3. Li X, He Y, Ruiz CH, Koenig M, Cameron MD Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 2009, 37:1242-1250.
4. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer. Cancer 2012, 118:63-71.
5. Connolly RM, Rudek MA, Garrett-Mayer E, et al. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 2011, 127:153-162.